DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Myocardial Fibrosis Overview
- Therapeutics Development
- Pipeline Products for Myocardial Fibrosis - Overview
- Pipeline Products for Myocardial Fibrosis - Comparative Analysis
- Myocardial Fibrosis - Therapeutics under Development by Companies
- Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes
- Myocardial Fibrosis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Myocardial Fibrosis - Products under Development by Companies
- Myocardial Fibrosis - Products under Investigation by Universities/Institutes
- Myocardial Fibrosis - Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Evotec AG
- Galectin Therapeutics, Inc.
- GTx, Inc.
- Invivosciences, Inc.
- MandalMed, Inc.
- miRagen Therapeutics, Inc.
- Regulus Therapeutics Inc.
- Shire Plc
- TRACON Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/69q7l6/myocardial
